Oncology

IND filed:

  • TMUN ONC 001:PSMA CAR for prostate cancer
     

  • TMUN ONC 002:NY-ESO1 CRISPR edited PD-1 knockout TCR. This will be the first gene-edited TCR to enter human clinical studies in the United States, with initiation planned for 2H 2017. Tmunity plans to evaluate three potential indications in myeloma, sarcoma and melanoma.

Preclinical:
 

  • TMUN ONC 003:GFRa4 CAR for medullary thyroid cancer
     

  • TMUN ONC 004:MUC-1 CAR for solid tumors

Legal  |  Privacy  |  Cookies

Tmunity Therapeutics Inc.
3020 Market Street, Suite 535
Philadelphia, PA 19104

+1 215 966 1600

© 2018 Tmunity Therapeutics. All rights reserved.